Evaluation of LIAISON Treponema Screen, a novel recombinant antigen-based chemiluminescence immunoassay for laboratory diagnosis of syphilis

Clin Diagn Lab Immunol. 2005 Oct;12(10):1231-4. doi: 10.1128/CDLI.12.10.1231-1234.2005.

Abstract

The purpose of this study was to evaluate the diagnostic performance of LIAISON Treponema Screen (DiaSorin, Saluggia, Italy), a new automated chemiluminescence immunoassay (CLIA), in comparison with that of rapid plasma reagin (RPR) and the following currently used treponemal tests: hemagglutination test (TPHA), immunoenzymatic assay (EIA), and Western blot (WB). First, a retrospective study was performed with a panel of 2,494 blood donor sera, a panel of 131 clinical and serologically characterized syphilitic sera, and 96 samples obtained from subjects with potentially interfering diseases or conditions. A prospective study was also performed by testing 1,800 unselected samples submitted to the Microbiology Laboratory of the St. Orsola Hospital in Bologna, Italy, for routine screening for syphilis. As expected, RPR was the least specific method, especially when potentially cross-reacting sera were tested. On the contrary, all of the treponemal tests proved to be very specific (99.9%) and they performed with the following sensitivities: 100% (WB), 99.2% (CLIA), 95.4% (EIA), and 94.7% (TPHA).

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Antigens, Bacterial*
  • Cross Reactions / immunology
  • Humans
  • Immunoassay / methods
  • Immunoassay / standards
  • Luminescent Measurements
  • Recombinant Proteins
  • Sensitivity and Specificity
  • Syphilis / diagnosis*
  • Syphilis Serodiagnosis / methods*
  • Syphilis Serodiagnosis / standards
  • Treponema / immunology
  • Treponema / isolation & purification*

Substances

  • Antigens, Bacterial
  • Recombinant Proteins